Biotech Valuation with rNPV: Pricing Pipelines Under Risk

Why Standard Valuation Breaks Down

You can't value a pre-revenue biotech with a P/E ratio — there are no earnings. You can't use a simple discounted cash flow either, because most pipeline drugs will fail, and a naive DCF that assumes success wildly overvalues the company. The standard tool the industry uses instead is risk-adjusted net present value (rNPV), which prices a pipeline by weighting each program's future cash flows by its probability of success.

How rNPV Works

For each drug program, rNPV builds an estimate from a few inputs:

1. Peak sales. What the drug could earn at maturity, based on the target indication's patient population, pricing, and competition.
2. Cash-flow timeline. When revenue starts (after approval), how it ramps, and when patents or biosimilars erode it.
3. Costs. Remaining trial costs, plus commercial and manufacturing costs.
4. Probability of success (PoS). The chance the program reaches market from its current phase — the most important and most subjective input.
5. Discount rate. A high rate (often 10–15%+) reflecting biotech's risk.

The future cash flows are discounted to today and multiplied by the probability of success. Summing the rNPV of every program, then adjusting for cash and debt, yields an enterprise value you can compare to the market cap.

Probability of Success Drives Everything

The single most consequential input is PoS, and it changes dramatically by stage. Historical industry data show roughly:

• Phase 1 → approval: on the order of ~10% across indications.
• Phase 2 → approval: roughly ~15–20%.
• Phase 3 → approval: often ~50% or higher, varying widely by therapeutic area.

These are averages; oncology historically runs lower, some other areas higher. The practical point: a successful Phase 3 readout is a massive rNPV event, because it can jump a program's PoS from ~50% toward ~90% (the remaining regulatory risk), re-rating the whole valuation. This is why pivotal readouts and PDUFA decisions move biotech stocks so violently — they're repricing the probability term.

How to Use rNPV Without Fooling Yourself

rNPV is powerful but easy to abuse, because small input changes swing the output enormously:

• Stress-test peak sales. Be honest about competition, pricing pressure, and realistic penetration. Optimistic peak-sales assumptions are the most common way rNPV models flatter a stock.
• Use defensible PoS. Anchor to historical base rates for the stage and indication; don't assume your favorite drug beats the average without a reason.
• Mind the discount rate. A small change has a large effect on long-dated cash flows.
• Run scenarios, not a point estimate. A bear/base/bull range is more honest than a single number that pretends to precision.

The goal isn't a "correct" price — it's a disciplined framework for comparing the market's implied assumptions to your own. If the market cap implies a PoS or peak-sales number far above what's defensible, that's the insight.

Connecting rNPV to Catalysts

rNPV makes explicit why catalysts matter: each successful trial readout raises a program's probability term, and each failure can zero it out. Tracking the catalyst calendar is, in effect, tracking the events that will revalue the model.

Applying It

Build a simple rNPV for the lead programs of any clinical-stage biotech you're serious about: estimate peak sales, apply a base-rate PoS for the stage, discount, and compare the sum to the enterprise value. Then ask what the market is assuming and whether you agree.

Review a company's pipeline, financials, and cash runway on its company page, and line the value-driving readouts up on the catalyst calendar. rNPV won't tell you a drug will work — but it will tell you whether the price already assumes it does.